Brain natriuretic peptide and N-terminal brain natriuretic peptide for the diagnosis of hemodynamically significant patent ductus arteriosus in preterm neonates

Primary objective
  • To determine the diagnostic accuracy of the cardiac biomarkers BNP and NT-proBNP for diagnosis of hemodynamically significant patent ductus arteriosus (hsPDA) in preterm neonates
  • To explore possible sources of heterogeneity among studies evaluating BNP and NT-proBNP, including type of commercial assay, chronological age of the patient at testing, gestational age at birth, whether used to initiate medical or surgical treatment, test threshold, and criteria of the reference standard (type of echocardiographic parameter used for diagnosis, clinical symptoms or physical signs if data were available)
  • To compare BNP and NT-proBNP index tests in a direct or an indirect comparison

We plan to perform the following subgroup analyses if data are available.

  • Type of commercial test assay used for BNP and NT-proBNP, as measurements may vary with each commercial assay.
  • Effects of postmenstrual age (in days) at testing: BNP and NT-proBNP levels are higher at birth and then decline over time and vary by gestational age at birth.
  • Whether test results were used to initiate medical or surgical treatment for PDA.

This is a protocol.

Share/Save